ALXN – Alexion Pharmaceuticals, Inc. – Fundamental analysis, financial statements, key ratios, and fair value analysis

Alexion Pharmaceuticals, Inc.

Healthcare
Biotechnology
106
5.79
5.78%
139.01
93.94
Stock Current Price
Change
Change %
52 Week High
52 Week Low

Financial Ratios

Earnings per Share (EPS)0.69
EPS Estimate Currrent Qtr1.61
Book Value Per Share41.1
Market Cap 24 Billion
PE Ratio 146.1
Dividend YieldNA

Stock Yield

Stock Return 7 Days3.48%
Stock Return 15 Days-11.25%
Stock Return 30 Days -22.52%
Stock Return 3 Months-28.46%
Stock Return One Year-21.64%
Stock Return 3 Years-21.52%

Stock Technical Analysis

Relative Strengh Index (14)23.18
Average True Range (14)4.97
Momentum (14)-16.8
Simple Moving Average (14) -16.8
Time Series Forecast (14)91.07
Time Series Forecast (30) 122.79

Stock News

NewsSourcePublished
See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.Yahoo Finance01/05/2019 13:02
Alexion to Present at the 37th Annual J.P. Morgan Healthcare ConferenceYahoo Finance01/02/2019 21:30
Alexion Comes Roaring Back To Protect Its Key Drug ProgramSeeking Alpha12/31/2018 13:00
Alexion’s (ALXN) Soliris Drives Growth Amid Pricing PressureYahoo Finance12/27/2018 23:21
Oppenheimer sees 1H19 risk for smid-cap biotechSeeking Alpha12/27/2018 09:42
Alexion’s Ultomiris Gets Early FDA Nod for Rare Blood DisorderYahoo Finance12/24/2018 14:26
Acorda Gets FDA Approval for Parkinson’s Disease Drug InbrijaYahoo Finance12/24/2018 13:59
Alexion to Present at the Goldman Sachs 11th Annual Healthcare CEO ConferenceYahoo Finance12/21/2018 21:30
‘Santa Comes Early’ As This Biotech Stock Grabs Its Fourth ApprovalYahoo Finance12/21/2018 21:25
Alexion Receives Early FDA Approval for ULTOMIRIS™ (Ravulizumab-cwvz) in Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)Yahoo Finance12/21/2018 16:23
U.S. FDA approves Alexion Pharma’s rare blood disorder drugYahoo Finance12/21/2018 15:50
Alexion’s Ultomiris wins FDA approvalSeeking Alpha12/21/2018 10:03
Agenus’ Stock Up 23% on Immuno-Oncology Deal With GileadYahoo Finance12/21/2018 14:19
Allakos (ALLK) Catches Eye: Stock Jumps 6.5%Yahoo Finance12/21/2018 13:49
Alexion Pharmaceuticals Enters Oversold TerritoryYahoo Finance12/20/2018 11:48
Vertex’s (VRTX) 3rd Study on Pain Drug Meets Primary EndpointYahoo Finance12/19/2018 14:12

Financial Statements

index2014201520162017
Revenue2 Billion3 Billion3 Billion4 Billion
Cost of Revenue174 Million233 Million258 Million454 Million
Gross Profit2 Billion2 Billion3 Billion3 Billion
Gross Margin (%)92.21%91.05%91.62%87.21%
Selling General and Administrative Expense630 Million863 Million953 Million1 Billion
Other operating expenses555 Million962 Million1 Billion1 Billion
Earning Before Interest and Taxes EBIT875 Million546 Million673 Million646 Million
EBIT/Operating Margin (%)39.17%20.96%21.82%18.20%
Interest Expense3 Million48 Million97 Million98 Million
Other non-operating expenses/income0000
Earnings before Tax872 Million498 Million576 Million548 Million
Income Tax Expense215 Million354 Million177 Million104 Million
Net Income657 Million144 Million399 Million443 Million
Net Margin (%)29.41%5.55%12.95%12.48%
Earnings per share from operating income0.4085315.642490.9575440.739951
Earnings per Diluted Share3.260.671.761.97
Dividends per Basic Common Share0000
Weighted average number of shares outstanding202 Million216 Million227 Million225 Million
index2017 Q42018 Q12018 Q22018 Q3
Revenue910 Million931 Million1 Billion1 Billion
Cost of Revenue144 Million92 Million95 Million91 Million
Gross Profit766 Million839 Million950 Million936 Million
Gross Margin (%)84.16%90.16%90.88%91.17%
Selling General and Administrative Expense296 Million257 Million277 Million259 Million
Other operating expenses354 Million206 Million1 Billion310 Million
Earning Before Interest and Taxes EBIT115 Million376 Million-394 Million367 Million
EBIT/Operating Margin (%)12.66%40.36%-0.00%35.72%
Interest Expense25 Million24 Million25 Million25 Million
Other non-operating expenses/income0000
Earnings before Tax90 Million352 Million-419 Million342 Million
Income Tax Expense60 Million102 Million39 Million11 Million
Net Income30 Million249 Million-457 Million331 Million
Net Margin (%)3.33%26.76%-0.00%32.24%
Earnings per share from operating income27.1571.35877-00.753871
Earnings per Diluted Share0.141.11-21.47
Dividends per Basic Common Share0000
Weighted average number of shares outstanding216 Million224 Million223 Million225 Million
index2014201520162017
Cash and Equivalents944 Million1 Billion966 Million584 Million
Trade and Non Trade Receivables433 Million533 Million650 Million726 Million
Inventory176 Million290 Million375 Million460 Million
Other current assets3 Billion3 Billion3 Billion2 Billion
Current Assets3 Billion2 Billion3 Billion3 Billion
Total Non-Current Assets1 Billion11 Billion11 Billion11 Billion
Total Assets4 Billion13 Billion13 Billion14 Billion
Trade and Non Trade Payables44 Million57 Million64 Million71 Million
Other current liabilities563 Million652 Million759 Million882 Million
Current Liabilities607 Million709 Million823 Million952 Million
Liabilities Non Current293 Million4 Billion4 Billion4 Billion
Accumulated Retained Earnings Deficit1 Billion1 Billion2 Billion2 Billion
Shareholder’s equity other2 Billion7 Billion7 Billion7 Billion
Shareholders Equity3 Billion8 Billion9 Billion9 Billion
Noncontrolling interests1 Billion1 Billion2 Billion2 Billion
Total Assets4 Billion13 Billion13 Billion14 Billion
index2017 Q42018 Q12018 Q22018 Q3
Cash and Equivalents584 Million512 Million728 Million1 Billion
Trade and Non Trade Receivables726 Million777 Million854 Million910 Million
Inventory460 Million456 Million463 Million433 Million
Other current assets2 Billion2 Billion2 Billion3 Billion
Current Assets3 Billion3 Billion3 Billion3 Billion
Total Non-Current Assets11 Billion11 Billion11 Billion11 Billion
Total Assets14 Billion14 Billion13 Billion14 Billion
Trade and Non Trade Payables71 Million57 Million59 Million52 Million
Other current liabilities882 Million885 Million986 Million975 Million
Current Liabilities952 Million942 Million1 Billion1 Billion
Liabilities Non Current4 Billion4 Billion4 Billion4 Billion
Accumulated Retained Earnings Deficit2 Billion2 Billion2 Billion2 Billion
Shareholder’s equity other7 Billion7 Billion7 Billion7 Billion
Shareholders Equity9 Billion9 Billion9 Billion9 Billion
Noncontrolling interests2 Billion2 Billion2 Billion2 Billion
Total Assets14 Billion14 Billion13 Billion14 Billion
index2014201520162017
Net Cash Flow from Operations640 Million675 Million1 Billion1 Billion
Capital Expenditure-137 Million-286 Million-333 Million-357 Million
Net Cash Flow from Investing-223 Million-4 Billion-288 Million-918 Million
Net Cash Flow from Financing7 Million3 Billion-836 Million-597 Million
Cash and Equivalents944 Million1 Billion966 Million584 Million
index2017 Q42018 Q12018 Q22018 Q3
Net Cash Flow from Operations258 Million299 Million-344 Million387 Million
Capital Expenditure-88 Million-67 Million-63 Million-41 Million
Net Cash Flow from Investing700 Thousand-255 Million568 Million105 Million
Net Cash Flow from Financing-226 Million-124 Million7 Million11 Million
Cash and Equivalents584 Million512 Million728 Million1 Billion

Stock Price History

table